Changes in vitreous VEGF, bFGF and fibrosis in proliferative diabetic retinopathy after intravitreal bevacizumab

International Journal of Ophthalmology

Volumn 8, Issue 6, 2015, Pages 1202-1206

  Li, Jiu Ke ^a   Wei, Fang ^a   Jin, Xiao Hong ^a   Dai, Yuan Min ^a   Cui, Hu Shan ^a   Li, Yu Min ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Basic fibroblast growth factor; Bevacizumab; Fibrosis; Proliferative diabetic retinopathy; Vascular endothelial growth factor

Indexed keywords

EID: 84947077415     PISSN: 22223959     EISSN: 22274898     Source Type: Journal    
DOI: 10.3980/j.issn.2222-3959.2015.06.22     Document Type: Article

References (22)

1. Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet 2010;376 (9735): 124-136
2. Fong DS, Aiello LP, Ferris FL 3rd, Klein R. Diabetic retinopathy. Diabetes Care 2004;27 (10):2540-2553
3. Hiscott P, Wong D, Grierson I. Challenges in ophthalmic pathology: the vitreoretinalmembrane biopsy. Eye(Lond) 2000;14(4):549-559
4. Mohan N, Monickaraj F, Balasubramanyam M, Rema M, Mohan V. Imbalanced levels of angiogenic and angiostatic factors in vitreous, plasma and postmortem retinal tissue of patients with proliferative diabetic retinopathy. J Diabetes Complications 2012;26(5):435-441
5. Zhou J, Wang S, Xia X. Role of intravitreal inflammatory cytokines and angiogenic factors in proliferative diabetic retinopathy. Curr.Eye.Res 2012; 37(5):416-420
6. Cui JZ, Chiu A, Maberley D, Ma P, Samad A, Matsubara JA. Stage specificity of novel growth factor expression during development of proliferative vitreoretinopathy. Eye (Lond) 2001;21,(2): 200-208
7. Wirostko B, Wong TY, Simo R. Vascular endothelial growth factor and diabetic complications. Prog Retin Eye Res 2008;27(6):608-621
8. Beranek M, Kolar P, Tschoplova S, Kankova K, Vasku A. Genetic variation and plasma level of the basic fibroblast growth factor in proliferative diabetic retinopathy. Diabetes Res Clin Pract 2008;79 (2): 362-367
9. Hueber A, Wiedemann P, Esser P, Heimann K. Basic fibroblast growth factor mRNA, bFGF peptide and FGF receptor in epiretinal membranes of intraocular proliferative disorders (PVR and PDR). Int Ophthalmol 1996-1997;20(6):345-350
10. Zhao LQ, Zhu H, Zhao PQ, Hu YQ. A systematic review and meta-analysis of clinical outcomes of vitrectomy with or without intravitreal bevacizumab pretreatment for severe diabetic retinopathy. Br J Ophthalmol 2011; 95 (9):1216-1222
11. di Lauro R, De Ruggiero P, di Lauro R, di Lauro MT, Romano MR. Intravitreal bevacizumab for surgical treatment of severe proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 2010;248 (6): 785-791
12. Arevalo JF, Maia M, Flynn HW Jr, Saravia M, Avery RL, Wu L, Eid Farah M, Pieramici DJ, Berrocal MH, Sanchez JG. Tractional retinal detachment followingintravitreal bevacizumab (Avastin) in patients with severe proliferative diabeticretinopathy. Br J Ophthalmol 2008;92 (2): 213-216
13. El-Sabagh HA, Abdelghaffar W, Labib AM, Mateo C, Hashem TM, Al-Tamimi DM, Selim AA. Preoperative intravitreal bevacizumab use as an adjuvant to diabetic vitrectomy: histopathologic findings and clinical implications. Ophthalmology 2011; 118(4):636-641
14. Cross MJ, Claesson-Welsh L. FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition. Trends Pharmacol Sci 2001; 22 (4):201-207
15. Dowlati A, Gray R, Sandler AB, Schiller JH, Johnson DH. Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab-an Eastern Cooperative Oncology Group Study. Clin Cancer Res 2008;14(5):1407-1412
16. Kuiper EJ, Van Nieuwenhoven FA, de Smet MD, van Meurs JC, Tanck MW, Oliver N, Klaassen I, Van Noorden CJ, Goldschmeding R, Schlingemann RO. The angio-fibrotic switch of VEGF and CTGF in proliferative diabetic retinopathy. PLoS One 2008;3(7):e2675
17. Arbab AS. Activation of alternative pathways of angiogenesis and involvement of stem cells following anti-angiogenesis treatment in glioma. Histol Histopathol 2012;27(5):549-557
18. de Oliveira Dias JR, Rodrigues EB, Maia M, Magalhães O Jr, Penha FM, Farah ME. Cytokines in neovascular age-related macular degeneration: fundamentals of targeted combination therapy. Br J Ophthalmol 2011; 95 (12):1631-1637
19. Okada-Ban M, Thiery JP, Jouanneau J. Fibroblast growth factor-2. Int J Blochem Cell Biol 2000;32(3):263-267
20. Sohn EH, He S, Kim LA, Salehi-Had H, Javaheri M, Spee C, Dustin L, Hinton DR, Eliott D. Angiofibrotic response to vascular endothelial growth factor inhibition in diabetic retinal detachment: report no.1. Arch Ophthalmol 2012;130(9):1127-1134
21. Hwang JC, Del Priore LV, Freund KB, Chang S, Iranmanesh R. Development of subretinal fibrosis after anti-VEGF treatment in neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2011;42(1):6-11
22. Boulton M, Gregor Z, McLeod D, Charteris D, Jarvis-Evans J, Moriarty P, Khaliq A, Foreman D, Allamby D, Bardsley B. Intravitreal growth factors in proliferative diabetic retinopathy: correlation with neovascular activity and glycaemic management. Br J Ophthalmol 1997;81(3):228-233